GTHX
NASDAQ:GTHX
G1 Therapeutics, Inc.
- Stock
7.16
+0.14%
0.01
news - May 23, 2025 - 15:31
FDA Greenlights GSK’s Nucala for Eosinophilic COPD
The U.S. Food and Drug Administration (FDA) approved GSK’s Nucala (mepolizumab) as an add-on treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. The approval is based on positive results from MATINEE and METREX Phase III trials, which showed Nucala reduced exacerbations in patients with a blood eosinophil count (BEC) ≥150 cells/µL. The drug is now available in the U.S., with regulatory submissions ongoing in China and Europe.
contractpharma.comnews - May 20, 2025 - 16:05
Cancer CDK Inhibitors Market Expands from $9.3 Bn in 2023 to $13.8
The global Cancer CDK Inhibitors Market reached $9.3 billion in 2023 and is projected to reach $13.8 billion by 2031, growing at a 5.2% CAGR. The market is analyzed in a report by DataM Intelligence, highlighting key players like Pfizer, Eli Lilly, and Novartis. A 2024 trial by Carrick Therapeutics combines CDK7 inhibitor samuraciclib with estrogen receptor degrader vepdegestrant for ER+ metastatic breast cancer. The market is segmented by drug type, cancer type, and distribution channel, with coverage across six regions including North America, Europe, Asia Pacific, and the Middle East.
openpr.comnews - Apr 10, 2025 - 07:17
PD-L1 Metastatic Non-small Cell Lung Cancer Therapeutics
DelveInsight's report on PD-L1 Metastatic Non-small Cell Lung Cancer provides insights into the market size, epidemiology, and forecast for the period up to 2032. The report highlights a significant growth in the number of incident cases, especially in the United States and EU5 countries, attributed to the launch of new therapies. Leading companies include Gilead Sciences, BieGene, GlaxoSmithKline, Arcus Biosciences, Hoffmann-La Roche, and others. Key therapies in the pipeline are KEYTRUDA, OPDIVO, Sugemalimab, and Datopotamab Deruxtecan.
openpr.comnews - Mar 29, 2025 - 01:09
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress
Relmada Therapeutics Inc. reported a mixed sentiment during its Q4 earnings call, highlighting successful strategic acquisitions and promising pipeline developments. The company acquired NDV-01 and Sepranolone, focusing on high-grade non-muscle invasive bladder cancer and Tourette syndrome, respectively. Despite these advancements, the discontinuation of REL-1017 and reevaluation of REL-P11 due to cash burn and regulatory challenges present ongoing hurdles. The company's cash reserves decreased from $96.3 million to $44.9 million, and it plans to present initial proof-of-concept data for NDV-01 at the American Urological Association Meeting in April 2025.
tipranks.comnews - Mar 25, 2025 - 22:00
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
The U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women and children aged 12 and older, weighing 40 kg or more. This approval is based on the results of phase 3 trials, EAGLE-2 and EAGLE-3, which demonstrated Blujepa's noninferiority and superiority to nitrofurantoin. Blujepa is the first oral antibiotic in nearly three decades for the treatment of uUTIs caused by specific bacteria. The approval highlights the growing need for effective treatments for recurrent infections and antibiotic resistance.
elpasoinc.comDescription
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or t...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus